XENE · Categories · Form 4

XENE - SEC Form 4 insider transactions

Xenon Pharmaceuticals Inc. (XENE) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for XENE

• 1d
  Director Patou Gary sold $70,251 worth of shares (1,322 units at $53.14) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 24,896 units (SEC Form 4) to cover withholding tax

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 1d
  Director Cannon Gillian sold $63,237 worth of shares (1,190 units at $53.14) as part of a pre-agreed trading plan, decreasing direct ownership by 45% to 1,455 units (SEC Form 4) to satisfy tax liability

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 6d
  Director Patou Gary converted options into 2,645 shares, increasing direct ownership by 11% to 26,218 units (SEC Form 4)

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 6d
  Director Machado Patrick converted options into 2,645 shares (SEC Form 4)

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 6d
  Director Gover Justin D. converted options into 2,645 shares (SEC Form 4)

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 6d
  Director Garofalo Elizabeth A. converted options into 2,645 shares (SEC Form 4)

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 6d
  Director Gannon Steven converted options into 2,645 shares and covered exercise/tax liability with 1,416 shares, increasing direct ownership by 12% to 11,870 units (SEC Form 4) to cover withholding tax

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 6d
  Director Cannon Gillian converted options into 2,645 shares (SEC Form 4)

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 6d
  Director Svoronos Dawn converted options into 2,645 shares and covered exercise/tax liability with 1,416 shares, increasing direct ownership by 5% to 26,229 units (SEC Form 4) to satisfy withholding tax

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 27d
  Director Gannon Steven exercised 3,500 shares at a strike of $7.38, increasing direct ownership by 49% to 10,641 units (SEC Form 4)

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 88d
  Chief Medical Officer Kenney Christopher John converted options into 3,750 shares and sold $77,867 worth of shares (1,410 units at $55.23), increasing direct ownership by 49% to 7,069 units (SEC Form 4)

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 88d
  Chief Legal Officer Difabio Andrea sold $74,112 worth of shares (1,342 units at $55.22) and converted options into 3,750 shares, increasing direct ownership by 49% to 7,301 units (SEC Form 4)

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 88d
  PRESIDENT & CEO Mortimer Ian converted options into 12,500 shares and sold $403,584 worth of shares (7,308 units at $55.23), increasing direct ownership by 35% to 19,923 units (SEC Form 4)

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 90d
  Chief Legal Officer Difabio Andrea converted options into 7,500 shares and sold $156,702 worth of shares (2,607 units at $60.11) (SEC Form 4)

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 90d
  Chief Medical Officer Kenney Christopher John sold $166,559 worth of shares (2,771 units at $60.11) and converted options into 7,500 shares (SEC Form 4)

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 90d
  PRESIDENT & CEO Mortimer Ian exercised 290,000 shares at a strike of $6.28 and sold $16,966,500 worth of shares (281,269 units at $60.32), increasing direct ownership by 146% to 14,731 units (SEC Form 4)

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 151d
  SEC Form 4 filed by Chief Medical Officer Kenney Christopher John

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 151d
  SEC Form 4 filed by Chief Commercial Officer Cline Darren S

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 151d
  SEC Form 4 filed by Chief Legal Officer Difabio Andrea

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 151d
  SEC Form 4 filed by PRESIDENT & CEO Mortimer Ian

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 158d
  PRESIDENT & CEO Mortimer Ian exercised 40,000 shares at a strike of $7.49 and sold $1,777,093 worth of shares (40,000 units at $44.43) (SEC Form 4)

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 182d
  PRESIDENT & CEO Mortimer Ian sold $1,142,513 worth of shares (25,205 units at $45.33), decreasing direct ownership by 81% to 6,000 units (SEC Form 4)

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 188d
  PRESIDENT & CEO Mortimer Ian sold $4,366 worth of shares (97 units at $45.01), decreasing direct ownership by 0.31% to 31,205 units (SEC Form 4)

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 235d
  SEC Form 4 filed by Chief Financial Officer Kelly Thomas Patrick

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 251d
  PRESIDENT, CEO & INTERIM CFO Mortimer Ian exercised 25,000 shares at a strike of $7.69 and sold $1,004,000 worth of shares (25,000 units at $40.16) (SEC Form 4)

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 350d
  SEC Form 4 filed by Chief Commercial Officer Cline Darren S

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 368d
  SEC Form 4 filed by Director Patou Gary

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 368d
  SEC Form 4 filed by Director Machado Patrick

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 368d
  SEC Form 4 filed by Director Gover Justin D.

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 368d
  SEC Form 4 filed by Director Garofalo Elizabeth A.

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 368d
  Director Gannon Steven sold $91 worth of shares (3 units at $30.48), decreasing direct ownership by 0.04% to 7,141 units (SEC Form 4)

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 368d
  SEC Form 4 filed by Director Cannon Gillian

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 368d
  SEC Form 4 filed by Director Svoronos Dawn

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 389d
  Director Gannon Steven exercised 5,144 shares at a strike of $12.57, increasing direct ownership by 257% to 7,144 units (SEC Form 4)

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 453d
  SEC Form 4 filed by PRESIDENT & CEO Mortimer Ian

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 453d
  SEC Form 4 filed by Chief Medical Officer Kenney Christopher John

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 453d
  SEC Form 4 filed by Chief Legal Officer Difabio Andrea

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 498d
  PRESIDENT & CEO Mortimer Ian sold $2,213,997 worth of shares (55,000 units at $40.25) and exercised 55,000 shares at a strike of $17.76 (SEC Form 4)

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 537d
  Chief Financial Officer Aulin Sherry exercised 25,334 shares at a strike of $10.79, covered exercise/tax liability with 6,625 shares and sold $770,912 worth of shares (18,709 units at $41.21) (SEC Form 4)

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 564d
  Director Patou Gary exercised 6,586 shares at a strike of $10.24, covered exercise/tax liability with 1,695 shares and sold $200,947 worth of shares (4,891 units at $41.08) (SEC Form 4)

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 734d
  SEC Form 4 filed by Patou Gary

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 734d
  SEC Form 4 filed by Machado Patrick

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 734d
  SEC Form 4 filed by Gover Justin D.

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 734d
  SEC Form 4 filed by Garofalo Elizabeth A.

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 734d
  SEC Form 4 filed by Gannon Steven

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 734d
  SEC Form 4 filed by Cannon Gillian

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 734d
  SEC Form 4 filed by Svoronos Dawn

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 819d
  SEC Form 4 filed by Von Seggern Christopher

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 819d
  SEC Form 4 filed by Aulin Sherry

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 819d
  SEC Form 4 filed by Kenney Christopher John

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 819d
  SEC Form 4 filed by Empfield James R.

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 819d
  SEC Form 4 filed by Robin Sherrington

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 819d
  SEC Form 4 filed by Difabio Andrea

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 819d
  SEC Form 4 filed by Mortimer Ian

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 820d
  Garofalo Elizabeth A. covered exercise/tax liability with 1,408 shares, sold $95,583 worth of shares (2,092 units at $45.69) and exercised 3,500 shares at a strike of $18.56 (SEC Form 4)

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 823d
  Robin Sherrington covered exercise/tax liability with 1,504 shares, sold $330,290 worth of shares (7,137 units at $46.28) and exercised 8,641 shares at a strike of $9.85 (SEC Form 4)

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 823d
  Gannon Steven sold $601,615 worth of shares (13,000 units at $46.28), decreasing direct ownership by 87% to 2,000 units (SEC Form 4)

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 889d
  Robin Sherrington disposed of 8,398 shares, decreasing direct ownership by 50% to 8,398 units (SEC Form 4)

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 902d
  Azab Mohammad exercised 4,320 shares at a strike of $9.85, increasing direct ownership by 6% to 74,225 units (SEC Form 4)

  4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
• 907d
  Patou Gary sold $311,898 worth of shares (7,598 units at $41.05) (SEC Form 4) (Amendment)

  4/A - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)

Other XENE categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends